PFIZER INC — Director's Dealing 2002

Sep 30, 2002

4 1 kam127.htm HARRY P. KAMEN - SEPTEMBER 27, 2002 FORM 4 SEC Form 4

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940 OMB APPROVAL OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response. . . . . 0.5

1. Name and Address of Reporting Person * Kamen, Harry P. (Last) (First) (Middle) Pfizer Inc. Att: Corporate Secretary 235 East 42nd Street (Street) New York, NY 10017 (City) (State) (Zip) 2. Issuer Name and Ticker or Trading Symbol Pfizer Inc (PFE) 3. I.R.S. Identification Number of Reporting Person, if an entity (voluntary) 4. Statement for (Month/Day/Year) September 27, 2002 5. If Amendment, Date of Original (Month/Day/Year) 6. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer Other Officer/Other Description 7. Individual or Joint/Group Filing (Check Applicable Line) X Individual Filing Joint/Group Filing

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 3. Transaction Code and Voluntary Code (Instr. 8) Code | V 4. Securities Acquired (A) or Disposed (D) Of (Instr. 3, 4, and 5) Amount | A/D | Price 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Owner- ship Form: Direct(D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)

Kamen, Harry P. - September 27, 2002

Form 4 (continued)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conver- sion or Exercise Price of Deri- vative Security	3. Transaction Date (Month/ Day/ Year)	4. Transaction Code and Voluntary (V) Code (Instr.8) Code | V	5. Number of Derivative Securities Acquired (A) or Disposed (D) Of (Instr. 3,4 and 5)	6. Date Exercisable(DE) and Expiration Date(ED) (Month/Day/Year) (DE) | (ED)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr.5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.4)	10. Owner- ship Form of Deriv- ative Security: Direct (D) or Indirect (I)
Phantom Stock Units	1-for-1	(1)	A | V	(A) 340	(2) | (2)	Common Stock - 340	(1)		D
Phantom Stock Units	1-for-1	(3)	A | V	(A) 380	(2) | (2)	Common Stock - 380	(3)		D
Phantom Stock Units	1-for-1	07/13/2002	A | V	(A) 47	(2) | (2)	Common Stock - 47	$32.35		D
Phantom Stock Units	1-for-1	(4)	A | V	(A) 98	(2) | (2)	Common Stock - 98	(4)		D
Phantom Stock Units	1-for-1	09/27/2002	A | &nbsp	(A) 411	(2) | (2)	Common Stock - 411	$28.58	45,158	D

Explanation of Responses :

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number. /s/ Margaret M. Foran for Harry P. Kamen ________ 09-30-2002 ** Signature of Reporting Person Date By Margaret M. Foran for Harry P. Kamen Page 2 SEC 1474 (3-99)

Kamen, Harry P. - September 27, 2002

Form 4 (continued)

FOOTNOTE Descriptions for Pfizer Inc (PFE) Form 4 - September 27, 2002 Harry P. Kamen Pfizer Inc. Att: Corporate Secretary 235 East 42nd Street New York, NY 10017 Explanation of responses: (1) These units were acquired on various dates during the first quarter of 2002 on the basis of prices ranging from $39.74 to $41.25 per unit. (2) These units represent deferred director's compensation (including dividend equivalents thereon) that is settled in cash following the reporting person's retirement from the Board of Directors. (3) These units were acquired on various dates during the second quarter of 2002 on the basis of prices ranging from $35.00 to $39.08 per unit. (4) These units were acquired on various dates during the month of August 2002 on the basis of prices ranging from $29.75 to $32.86 per unit.

Page 3